AlloVir, Inc. (NASDAQ:ALVR) CEO Diana Brainard Sells 34,435 Shares

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 34,435 shares of the stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $5.08, for a total value of $174,929.80. Following the sale, the chief executive officer now directly owns 601,607 shares in the company, valued at approximately $3,056,163.56. The sale was disclosed in a document filed with the SEC, which is available at this link.

Diana Brainard also recently made the following trade(s):

• On Friday, November 18th, Diana Brainard sold 4,515 shares of AlloVir stock. The shares were sold at an average price of $7.27, for a total value of $32,824.05.

AlloVir Trading Down 2.3 %

Shares of ALVR opened at $5.13 on Tuesday. AlloVir, Inc. has a 12 month low of $3.17 and a 12 month high of $10.29. The stock has a fifty day moving average price of $6.23 and a 200-day moving average price of $6.94. The firm has a market cap of $477.93 million, a PE ratio of -1.83 and a beta of 0.87.

AlloVir (NASDAQ:ALVR – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. As a group, research analysts forecast that AlloVir, Inc. will post -2.28 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, SVB Leerink decreased their price objective on AlloVir from $25.00 to $19.00 and set an “outperform” rating for the company in a report on Monday.

Hedge Funds Weigh In On AlloVir

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in AlloVir in the 3rd quarter worth $25,000. Amalgamated Bank purchased a new position in AlloVir in the 1st quarter worth $33,000. Nisa Investment Advisors LLC raised its stake in AlloVir by 33.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,210 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the last quarter. Corton Capital Inc. purchased a new position in AlloVir in the 2nd quarter worth $41,000. Finally, Delphia USA Inc. purchased a new position in AlloVir in the 2nd quarter worth $44,000.

AlloVir Company Profile

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.